Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus
出版年份 2023 全文链接
标题
Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus
作者
关键词
-
出版物
KARDIOLOGIYA
Volume 62, Issue 12, Pages 64-72
出版商
APO Society of Specialists in Heart Failure
发表日期
2023-01-13
DOI
10.18087/cardio.2022.12.n1838
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes
- (2020) Takehiro Hashikata et al. HEART AND VESSELS
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds/Leeds Teaching Hospitals NHS Trust, LIGHT Laboratories, Clarendon Way
- (2020) F. Cosentino et al. RUSSIAN JOURNAL OF CARDIOLOGY
- Empagliflozin treatment effects across categories of baseline HbA1c , body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes
- (2020) Silvio E. Inzucchi et al. DIABETES OBESITY & METABOLISM
- Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes
- (2019) Peili Wu et al. HORMONE AND METABOLIC RESEARCH
- The effect of dapagliflozin treatment on epicardial adipose tissue volume
- (2018) Takao Sato et al. Cardiovascular Diabetology
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization
- (2017) Liang Xu et al. Adipocyte
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Leptin-adiponectin ratio in pre-diabetic patients undergoing percutaneous coronary intervention
- (2015) Pham Anh Hong Nguyen et al. ACTA CARDIOLOGICA
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
- (2015) Ian J Neeland et al. Diabetes & Vascular Disease Research
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- Long-term prognostic value of preprocedural adiponectin levels in patients undergoing percutaneous coronary intervention
- (2013) Cédric Delhaye et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Notice
- (2012) Kidney International Supplements
- Determination of the cut-off plasma adiponectin level associated with a lower risk of restenosis in patients with stable angina
- (2011) Takahiro Mito et al. CORONARY ARTERY DISEASE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started